JP2024515885A - パーキンソン病を処置及びモニタリングするための方法 - Google Patents

パーキンソン病を処置及びモニタリングするための方法 Download PDF

Info

Publication number
JP2024515885A
JP2024515885A JP2023566921A JP2023566921A JP2024515885A JP 2024515885 A JP2024515885 A JP 2024515885A JP 2023566921 A JP2023566921 A JP 2023566921A JP 2023566921 A JP2023566921 A JP 2023566921A JP 2024515885 A JP2024515885 A JP 2024515885A
Authority
JP
Japan
Prior art keywords
compound
subject
lrrk2
disease
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515885A5 (https=
Inventor
ジェニングス，ダナ・エル
ダーヤニ，ヴィナイ・エム
ハントワーク－ロドリゲス，サラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of JP2024515885A publication Critical patent/JP2024515885A/ja
Publication of JP2024515885A5 publication Critical patent/JP2024515885A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2023566921A 2021-04-30 2022-04-29 パーキンソン病を処置及びモニタリングするための方法 Pending JP2024515885A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182207P 2021-04-30 2021-04-30
US63/182,207 2021-04-30
PCT/US2022/026898 WO2022232487A1 (en) 2021-04-30 2022-04-29 Methods for treating and monitoring parkinson's disease

Publications (2)

Publication Number Publication Date
JP2024515885A true JP2024515885A (ja) 2024-04-10
JP2024515885A5 JP2024515885A5 (https=) 2025-05-09

Family

ID=83847331

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566921A Pending JP2024515885A (ja) 2021-04-30 2022-04-29 パーキンソン病を処置及びモニタリングするための方法

Country Status (9)

Country Link
US (1) US20240207266A1 (https=)
EP (1) EP4329763A4 (https=)
JP (1) JP2024515885A (https=)
CN (1) CN117769422A (https=)
AU (1) AU2022267325A1 (https=)
CA (1) CA3217230A1 (https=)
MX (1) MX2023012851A (https=)
TW (1) TW202308635A (https=)
WO (1) WO2022232487A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025051214A1 (zh) * 2023-09-07 2025-03-13 上海翊石医药科技有限公司 一种芳杂环类化合物及其制备方法
CN121226329A (zh) * 2024-06-28 2025-12-30 成都康弘药业集团股份有限公司 一种治疗或预防lrrk2介导的疾病的化合物
CN119119035B (zh) * 2024-08-30 2025-11-04 中山大学 一种ripk1激酶靶点抑制剂及其制备方法与应用
CN118878521B (zh) * 2024-09-26 2025-02-14 苏州美诺医药科技有限公司 一种lrrk2抑制剂的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102091895B1 (ko) * 2012-05-03 2020-04-14 제넨테크, 인크. 파킨슨병의 치료에 사용하기 위한 lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체
WO2014059052A1 (en) * 2012-10-09 2014-04-17 Uab Research Foundation Methods and compositions for diagnosis and treatment of parkinson's disease and parkinsonism
SMT202100699T1 (it) * 2016-06-16 2022-01-10 Denali Therapeutics Inc Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi

Also Published As

Publication number Publication date
EP4329763A1 (en) 2024-03-06
CA3217230A1 (en) 2022-11-03
TW202308635A (zh) 2023-03-01
EP4329763A4 (en) 2025-03-05
MX2023012851A (es) 2024-03-19
AU2022267325A1 (en) 2023-11-16
WO2022232487A1 (en) 2022-11-03
US20240207266A1 (en) 2024-06-27
CN117769422A (zh) 2024-03-26

Similar Documents

Publication Publication Date Title
JP2024515885A (ja) パーキンソン病を処置及びモニタリングするための方法
Elkalioubie et al. Near-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizer
RU2759856C1 (ru) Новое соединение для прямого ингибирования активности asm, представляющее собой производное 2-амино-2-(1,2,3-триазол-4-ил)пропан-1,3-диола, и его применение
JP2012508737A5 (https=)
Rafehi et al. Highly variable pharmacokinetics of tyramine in humans and polymorphisms in OCT1, CYP2D6, and MAO-A
Mahoney-Crane et al. Neuronopathic GBA1L444P mutation accelerates glucosylsphingosine levels and formation of hippocampal alpha-synuclein inclusions
TW201142297A (en) Urinary triaosylceramide (Gb3) as a marker of cardiac disease
WO2023083288A1 (en) TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST
WO2019089988A1 (en) Isoindoline compositions and methods for treating neurodegenerative disease
JP5713887B2 (ja) 筋変性疾患の検出方法、及び治療効果判定方法
US20020064804A1 (en) Compositions and methods for detecting and quantifying COX-2 activity and 2-arachidonylglycerol metabolites
US20250177351A1 (en) Isoindoline compositions and methods for treating neurodegenerative disease
Tan et al. Rat hair metabolomics analysis reveals perturbations of unsaturated fatty acid biosynthesis, phenylalanine, and arachidonic acid metabolism pathways are associated with amyloid-β-induced cognitive deficits
Maloney et al. LRRK2 kinase activity regulates Parkinson’s disease-relevant lipids at the lysosome
US20200046693A1 (en) Compositions and methods for the treatment of zellweger spectrum disorder
Yang et al. Accumulated BCAAs and BCKAs contribute to the HFD-induced deterioration of Alzheimer's disease via a dysfunctional TREM2-related reduction in microglial β-amyloid clearance
van Harskamp et al. Development and validation of a new gas chromatography–tandem mass spectrometry method for the measurement of enrichment of Glyoxylate metabolism Analytes in Hyperoxaluria patients using a stable isotope procedure
US12576055B2 (en) Disease detection and treatment based on trimethyl-lysine levels
Suhre et al. Identification of a potential biomarker for FABP4 inhibition: the power of lipidomics in preclinical drug testing
Liu et al. Absorption, tissue disposition, and excretion of fasudil hydrochloride, a RHO kinase inhibitor, in rats and dogs
JP2022516995A (ja) 化膿性汗腺炎の治療用ｌｔａ４ｈ阻害剤
TW201805004A (zh) 用於預防具風險病患之阿茲海默症之㗁衍生物
Zeleznik et al. Plasma metabolomics of primary open-angle glaucoma in three prospective US cohorts and the UK Biobank
JP2026507930A (ja) グルコセレブロシダーゼアクチベータを使用した患者におけるパーキンソン病の処置
US20250302775A1 (en) Methods for the treatment of depression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250428